Cargando…
Therapeutic advances in COVID-19
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed millions of lives. Unlike the early days of the pandemic, when management decisions were based on extrapolations from in vitro data, case reports and case series, clinicians are now equipped with an armamentarium of...
Autores principales: | Murakami, Naoka, Hayden, Robert, Hills, Thomas, Al-Samkari, Hanny, Casey, Jonathan, Del Sorbo, Lorenzo, Lawler, Patrick R., Sise, Meghan E., Leaf, David E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574806/ https://www.ncbi.nlm.nih.gov/pubmed/36253508 http://dx.doi.org/10.1038/s41581-022-00642-4 |
Ejemplares similares
-
Author Correction: Therapeutic advances in COVID-19
por: Murakami, Naoka, et al.
Publicado: (2023) -
Reply to ‘Use of convalescent plasma in the treatment of COVID-19’
por: Murakami, Naoka, et al.
Publicado: (2023) -
COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panic
por: Al-Samkari, Hanny
Publicado: (2023) -
Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge
por: Miao, Jing, et al.
Publicado: (2022) -
Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice
por: Song, Fei, et al.
Publicado: (2021)